CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 14 (2) , 327-337
Abstract
No abstract availableKeywords
Funding Information
- Council of Scientific and Industrial Research (CSIR) New Delhi
This publication has 39 references indexed in Scilit:
- JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometryCell Death & Disease, 2012
- Current status of therapy for breast cancer worldwide and in JapanWorld Journal of Clinical Oncology, 2011
- Cationic nanoparticles for cancer therapyExpert Opinion on Drug Delivery, 2010
- A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid MalignanciesClinical Cancer Research, 2009
- Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2PLOS ONE, 2009
- Intratumoral Delivery of Paclitaxel in Solid Tumor from Biodegradable Hyaluronan Nanoparticle FormulationsAAPS PharmSciTech, 2009
- Nanoparticle therapeutics: an emerging treatment modality for cancerNature Reviews Drug Discovery, 2008
- Lapatinib: Current Status and Future Directions in Breast CancerThe Oncologist, 2006
- Chemotaxis towards hyaluronan is dependent on CD44 expression and modulated by cell type variation in CD44-hyaluronan bindingJournal of Cell Science, 2005
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979